Jubilant Pharmova Share Price
924.50+16.60 (+1.83%)
-12.14% past 1 Year
News
Jubilant Pharmova receives Rs 87.31 crore GST demand for FY23
Equity
JUBLPHARMA
Jubilant Pharmova receives CGST notice for Rs 52.75 crore IGST refund demand
Equity
JUBLPHARMA
Jubilant Pharmova gets USFDA nod for new Spokane fill-finish line
Equity
JUBLPHARMA
Jubilant Pharmova reports lower Q1 EBITDA and margin year on year
Equity
JUBLPHARMA
Jubilant Pharmova posts higher Q1 revenue on yearly basis
Equity
JUBLPHARMA
Jubilant Pharmova posts lower first quarter net profit year on year
Equity
JUBLPHARMA
Jubilant Pharmova unit gets USFDA tentative approval for pantoprazole suspension
Equity
JUBLPHARMA
Jubilant Pharmova Spokane plant completes USFDA inspection with 8 observations
Equity
JUBLPHARMA
Jubilant Pharmova - Quaterly Results
Equity
JUBLPHARMA
Jubilant Pharmova chairman guides for EBITDA margin improvement from H2 FY27 onward
Equity
JUBLPHARMA
Jubilant Pharmova CFO Arun Kumar Sharma resigns, Ashish Mukirwar appointed
Equity
JUBLPHARMA
Jubilant Pharmova Q4 EBITDA declines marginally with sharp margin compression YoY
Equity
JUBLPHARMA
Jubilant Pharmova Q4 revenue grows strongly year-on-year, signalling robust topline momentum
Equity
JUBLPHARMA
Jubilant Pharmova Q4 consolidated net profit declines year-on-year to Rs 120 crores
Equity
JUBLPHARMA
Jubilant Pharmova reports Profit after tax of 57.20 Crores, in the March 2026 quarter
Equity
JUBLPHARMA
Jubilant Pharmova informs about board meeting
Equity
JUBLPHARMA
Jubilant Pharmova - Quaterly Results
Equity
JUBLPHARMA
Jubilant Pharmova Q3 Revenue Grows 17% YoY to Rs 2120 Crores.
Equity
JUBLPHARMA
Jubilant Pharmova Q3 EBITDA at Rs 290 Crores, Slightly Up YoY from Rs 287 Crores; Margin Declines to 13.6%.
Equity
JUBLPHARMA
Jubilant Pharmova Q3 FY26 Profit Before Tax Declines YoY to Rs 130 Crores
Equity
JUBLPHARMA